1.      Abicht A, Muller JS, Lochmuller H. Congenital Myasthenic Syndromes Overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews((R)). Seattle (WA)1993.

2.      Arredondo J, Lara M, Gospe Jr. SM, Mazia CG, Vaccarezza M, Garcia-Erro M, et al. Choline Acetyltransferase Mutations Causing Congenital Myasthenic Syndrome: Molecular Findings and Genotype–Phenotype Correlations. Human Mutation. 2015;36(9):881–93.

3.      Benatar M, Cutter G, Kaminski HJ. The best and worst of times in therapy development for myasthenia gravis. Muscle & Nerve. 2023;67(1):12–6.

4.      Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term

5.      Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management. Neurol Ther. 2025.

6.      Della Marina A, Wibbeler E, Abicht A, Kolbel H, Lochmuller H, Roos A, et al. Long Term

7.      Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. Journal of Clinical Medicine. 2021;10(11):2235.

8.      Durmus H, Shen XM, Serdaroglu-Oflazer P, Kara B, Parman-Gulsen Y, Ozdemir C, et al.

9.      Effective in a Confirmatory Phase 3 Clinical Trial in LEMS. J Clin Neuromuscul Dis. 2019;20(3):111–9.

10.  efficacy in the treatment of neurological disorders: a systematic literature review. Ther Adv

11.  El-Wahsh S, Fraser C, Vucic S, Reddel S. Neuromuscular junction disorders: mimics and chameleons. Pract Neurol. 2024;24(6):467–77.

12.  Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 2015;14(5):461.

13.  Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, et al. Myasthenia

14.  Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes-A Retrospective Single Centre Cohort Study. Front Hum Neurosci. 2020;14:560860.

15.  follow-up. Neuromuscul Disord. 2018;28(4):315–22.

16.  Gnanarathne S, Ratnayake A, Thennewatte D, Isurindi UA. Congenital Myasthenic Syndrome in Pregnancy: A Case Report and Literature Review on Peripartum Management Strategy. Cureus. 2025;17(8):e89337.

17.  gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018;1412(1):82–9.

18.  Hajjar M, Markowitz J, Darras BT, Kissel JT, Srinivasan J, Jones HR. Lambert-Eaton

19.  Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol. 2013;48(2):95–104.

20.  Jacob S, Farrugia ME, Hewamadduma C, Norwood F, Hill M, Leite MI, et al. Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). Practical Neurology. 2025;25(5):422–37.

21.  Li W, Liu P, Cui W, Wang S, Ji Y, Zhang L, et al. Clinical characteristics of anti-AChR- MuSK-LRP4 antibody-negative myasthenia gravis in China. Muscle Nerve. 2023;67(6):481–8.

22.  Li Y, Peng Y, Yang H. Serological diagnosis of myasthenia gravis and its clinical significance. Ann Transl Med. 2023;11(7):290.

23.  literature review. Pediatr Neurol. 2014;50(1):11–7.

24.  Mantegazza R, Antonini G, Gastaldi M, Liguori R, Maestri M, Pegoraro E, et al. Use of

25.  Maselli RA, Ng JJ, Anderson JA, Cagney O, Arredondo J, Williams C, et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet. 2009;46(3):203–8.

26.  Morren JA, Levin KH, Shields RW. Diagnostic Accuracy of Single Fiber Electromyography for Myasthenia Gravis in Patients Followed Longitudinally. J Clin Neurophysiol. 2016;33(5):469–74.

27.  Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114–22.

28.  Neurol Disord. 2023;16:17562864231154306.

29.  O'Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Front Neurol. 2020;11:743.

30.  O'Hare M, Doughty C. Update on Ocular Myasthenia Gravis. Semin Neurol. 2019;39(6):749–60.

31.  Oh SJ. Amifampridines are the Most Effective Drugs for Treating Lambert-Eaton Myasthenic Syndrome With a Focus on Pediatric Lambert-Eaton Myasthenic Syndrome. J Clin Neurol. 2024;20(4):353–61.

32.  Ohno K, Ito M, Ohkawara B. Review of 40 genes causing congenital myasthenic syndromes. J Hum Genet. 2025.

33.  Pinto AA, De Seze J, Jacob A, Reddel S, Yudina A, Tan K. Comparison of IVIg and TPE

34.  Ramdas S, Beeson D, Dong YY. Congenital myasthenic syndromes: increasingly complex. Current Opinion in Neurology. 2024;37(5):493–501.

35.  Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF, Jr., Corse A, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve. 2020;62(3):333–43.

36.  Schara U, Christen HJ, Durmus H, Hietala M, Krabetz K, Rodolico C, et al. Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations. Eur J Paediatr Neurol. 2010;14(4):326–33.

37.  Shen XM, Selcen D, Brengman J, Engel AG. Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability. Neurology. 2014;83(24):2247–55.

38.  Shieh P, Sharma K, Kohrman B, Oh SJ. Amifampridine Phosphate (Firdapse) Is

39.  syndrome, an unrecognized treatable pediatric neuromuscular disorder: three patients and

40.  Tayade K, Salunkhe M, Agarwal A, Radhakrishnan DM, Srivastava AK. DOK7 congenital myasthenic syndrome responsive to oral salbutamol. QJM: An International Journal of Medicine. 2022;115(5):323–4.

41.  Yang J, Pan L, Liu Y, Wang Y. Transient Neonatal Myasthenia Gravis Born to a Mother with Asymptomatic MG: A Case Report. Degener Neurol Neuromuscul Dis. 2024;14:15–9.

42.  Yin Y, Cao J, Fan Y, Xu Y. COLQ-mutation congenital myasthenic syndrome in late adolescence: Case report and review of the literature. Heliyon. 2023;9(9):e19980.

43.  Ziaadini B, Ghaderi Yazdi B, Dirandeh E, Boostani R, Karimi N, Panahi A, et al. DOK7 congenital myasthenic syndrome: case series and review of literature. BMC Neurol. 2024;24(1):211.